San Diego, California (April 1, 2018) – In recent times the pharmaceutical and biotechnology industries is gradually inclining to outsource drug formulation development in order to shorten timeline, access a specific expertise, and provide added insurance against product failure. With developing strain to take prospective drugs candidates from revelation to human clinical trials as fast as possible, majority of the pharmaceutical and biotech organizations are outsourcing at least a portion of the advancement of their potential new medications. Outsourcing compresses the course of events of product development and gives a cost-effective substitute to including specialized resources. The changing needs in the current rapidly growing development environment direct that the assets must be adjusted in a fast manner to meet demands. Hence, outsourcing permits a variable cost structure, expanding resources and spending when important and diminishing when demand dies down. LATITUDE Pharmaceuticals Inc. is one such outsourcing Particle Size Distribution Analysis providing human and veterinary pharmaceutical industries with unique NCE and generic drug formulation development services along with proprietary drug delivery systems.
LATITUDE Pharmaceuticals Inc. was established in 2003 and since then the organization has performed more than 800 formulation development ventures for over 225 customer organizations and have built up an international reputation for creative methodologies, dependability, fast turnaround, fruitful formulations and overall customer satisfaction. The company was founded by Andrew X. Chen who is now its president and heads the research and development team. He has over two decades of experience in formulation covering little atom, peptide, protein, nucleic acid, and virus based pharmaceuticals all of which enables the company to quickly pinpoint key issues with troublesome compounds and rapidly create toxicology and business formulation for its customers. Andrew’s imaginative and innovative approach has prompted more 25 issued and pending formulation patents, a considerable lot of which name him as the sole inventor. Mathew A. Singer is the vice president and head of business development of LATITUDE Pharmaceuticals Inc.
With knowledgeable, skilled and experienced people on board, qualified and well-trained scientists, and state of the art analytical laboratories and equipments, LATITUDE Pharmaceuticals Inc. has been developing and manufacturing new drugs for various biotech and pharmaceutical companies around the world. All relevant information about them along with their expertise and specialties, services and capabilities, licensing opportunities, drug delivery systems and formulation platforms, and other details can be found on their official website, the link for which is http://latitudepharma.com/.
About LATITUDE Pharmaceuticals Inc.
LATITUDE Pharmaceuticals Inc. is a formulation development contract research company founded by Andrew X. Chen in 2003 to meet the growing demand of Controlled Release Oral Formulation Development in biotech and pharmaceutical industries. Since its inception, the company has done over 800 formulation development projects for more than 225 client organizations around the world.
LATITUDE Pharmaceuticals Inc.
Address: 9675 Businesspark Avenue
San Diego, CA 92131